Research statistics

SLU-PP-332 research: publications and trials

What has been published on SLU-PP-332: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether SLU-PP-332 works or is safe. For what it is and what the studies found, see the SLU-PP-332 profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

9

Since 2023

Publications in 2026 so far

4

Through November 15, 2026

Human clinical research

0.0%

0 of 9 classified

Registered clinical trials

0

ClinicalTrials.gov

Randomized controlled trials

0

Publications reporting an RCT in people

Systematic reviews and meta-analyses

1

Preclinical studies

88.9%

4 animal · 4 in vitro · 0 computational

Records that only mention it

1

Not counted above

Status in the library: Research only.

What to keep in mind

  • No human clinical publication is indexed: everything published so far is preclinical, a review or commentary.
  • Fewer than three randomized controlled trials are indexed.
  • More than 70% of the indexed publications are animal, cell or computational studies.
  • Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
  • Not a peptide: it is shown for completeness and left out of every peptide total.

Publications by year

SLU-PP-332 publications by year and evidence

2023, Preclinical (animal, in vitro, computational): 3 of 32024, Preclinical (animal, in vitro, computational): 1 of 12025, Preclinical (animal, in vitro, computational): 1 of 12026 (to date), Preclinical (animal, in vitro, computational): 3 of 42026 (to date), Reviews and meta-analyses: 1 of 4Preclinical (animal, in vitro, computational)Reviews and meta-analyses012342023202420252026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearPreclinical (animal, in vitro, computational)Reviews and meta-analysesTotal
2023303
2024101
2025101
2026 (to date)314

Study types

Animal study4
In vitro study4
Systematic review1

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health4
Musculoskeletal4
Cardiovascular1
Immune system1
Longevity and aging1

Registered clinical trials

A registration is not a result.

No registered trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].

    Revista medica de Chile · February 1, 2026 · Systematic review · cited 0 times · open access

    PMID 42024694 · DOI 10.4067/s0034-98872026000200237 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.

    Circulation · November 14, 2023 · Animal study · cited 67 times · open access

    PMID 37961903 · DOI 10.1161/circulationaha.123.066542 · Animal studies

  2. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.

    The American journal of pathology · September 17, 2023 · Animal study · cited 45 times · open access

    PMID 37717940 · DOI 10.1016/j.ajpath.2023.07.008 · Animal studies

  3. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.

    ACS chemical biology · March 29, 2023 · Animal study · cited 39 times · open access

    PMID 36988910 · DOI 10.1021/acschembio.2c00720 · Animal studies

  4. A Synthetic ERR Agonist Alleviates Metabolic Syndrome.

    The Journal of pharmacology and experimental therapeutics · January 17, 2024 · Animal study · cited 29 times · open access

    PMID 37739806 · DOI 10.1124/jpet.123.001733 · Animal studies

  5. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.

    Frontiers in physiology · July 7, 2025 · In vitro study · cited 4 times · open access

    PMID 40692696 · DOI 10.3389/fphys.2025.1616693 · In vitro studies

Latest publications

  1. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.

    Rapid communications in mass spectrometry : RCM · April 1, 2026 · In vitro study · cited 1 times · open access

    PMID 41588687 · DOI 10.1002/rcm.70039 · In vitro studies

  2. Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.

    International journal of biological macromolecules · March 16, 2026 · In vitro study · cited 0 times · open access

    PMID 41850449 · DOI 10.1016/j.ijbiomac.2026.151450 · In vitro studies

  3. Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.

    Drug testing and analysis · February 13, 2026 · In vitro study · cited 0 times

    PMID 41688415 · DOI 10.1002/dta.70035 · In vitro studies

  4. [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].

    Revista medica de Chile · February 1, 2026 · Systematic review · cited 0 times · open access

    PMID 42024694 · DOI 10.4067/s0034-98872026000200237 · Reviews and meta-analyses

  5. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.

    Frontiers in physiology · July 7, 2025 · In vitro study · cited 4 times · open access

    PMID 40692696 · DOI 10.3389/fphys.2025.1616693 · In vitro studies

  6. A Synthetic ERR Agonist Alleviates Metabolic Syndrome.

    The Journal of pharmacology and experimental therapeutics · January 17, 2024 · Animal study · cited 29 times · open access

    PMID 37739806 · DOI 10.1124/jpet.123.001733 · Animal studies

  7. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.

    Circulation · November 14, 2023 · Animal study · cited 67 times · open access

    PMID 37961903 · DOI 10.1161/circulationaha.123.066542 · Animal studies

  8. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.

    The American journal of pathology · September 17, 2023 · Animal study · cited 45 times · open access

    PMID 37717940 · DOI 10.1016/j.ajpath.2023.07.008 · Animal studies

  9. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.

    ACS chemical biology · March 29, 2023 · Animal study · cited 39 times · open access

    PMID 36988910 · DOI 10.1021/acschembio.2c00720 · Animal studies

Browse all 9 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: SLU-PP-332

((TITLE_ABS:"SLU-PP-332" OR CHEM:"SLU-PP-332" OR TITLE_ABS:"SLU-PP332" OR CHEM:"SLU-PP332")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). SLU-PP-332 research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/slu-pp-332